Chronicmyelocytic leukemia therapeutic pipeline analysis is expected to grow rapidly
due to the increasing prevalence of the disease, globally. Some of the main factors
driving the pipeline analysis for chronic myelocytic leukemia include increasing
aging population and rising prevalence of chronic myelocytic leukemia, and
increasing health awareness. Chronic myelocytic leukemia have high incidence
rate in men and is the second most common type of cancer occurring in male
adults. Women, above 50 years of age are at high risk to develop chronic
myelocytic leukemia.
Explore Report at: https://www.psmarketresearch.com/market-analysis/chronic-myelocytic-leukemia-therapeutics-pipeline-analysis
Chronic myeloid
leukemia is the tumour that occurs in blood cells and bone marrow, which is the
soft parts inside bones where blood cells are produced. Chronic myelocytic leukemia
usually occurs in middle-aged or older adults. It occurs due to the swapping of
DNA between chromosome 9 nine and chromosome 22. The resultant abnormal
chromosome is known as Philadelphia chromosome. This swapping forms a new gene,
BCR-ABL which is the type
of protein, tyrosine kinase. This protein causes chronic myelocytic leukemia
cells to grow and reproduce uncontrollable manner. One of the main cause of
chronic myelocytic leukemia is exposure to high radiation. The symptoms of
chronic myelocytic leukemia include stroke, dizziness, change in vision,
swollen glands, high fever, bruises, weight loss, pain in bones, short of
breath and night sweats. Chronic myeloid leukemia can be diagnosed by performing
a bone marrow test, complete blood count, FISH test and ultrasound. The
treatment for chronic myeloid leukemia includes drug therapy and stem cell
transplant.
Some of the companies having a pipeline of chronic myelocytic leukemia therapeutics include Bristol Myers Squibb Company, ARIAD Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hospira, Prism Pharma, Incyte Corp., Otsuka Pharmaceutical Co., Ltd., Bio-Path Holdings, Hybrigenics Corporation, Fusion Pharma LLC.
No comments:
Post a Comment